SAN FRANCISCO (EGMN) — Patients with metastatic renal cell carcinoma who develop hypertension when treated with sunitinib are less likely to have disease progression and to die than were their counterparts whose blood pressure remained within normal bounds, researchers reported at a symposium on genitourinary cancers.In a retrospective analysis of pooled data from four trials, patients developing sunitinib-induced hypertension had a roughly 50%-75% reduction in the risks of progression and death....